{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:00:54Z","timestamp":1776268854985,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Extramedullary relapse (EMR) of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT) is rare and challenging condition, associated with poor outcomes, especially in children. We describe a 5-year-old boy with therapy-related AML who developed bilateral facial palsy as the first sign of EMR, eight months after HSCT. Initial investigations, including bone marrow (BM), cerebrospinal fluid (CSF), and MRI, were inconclusive. Progressive symptoms and rising of minimal residual disease prompted repeated evaluations and, ultimately, led to the diagnosis of a bilateral extramedullary leukemic infiltration. The patient was treated with venetoclax combined with high-dose cytarabine and idarubicin, achieving complete resolution of the EMR and also first-ever molecular remission of the disease, further consolidated with a second HSCT. This case underscores the diagnostic challenges of EMR presenting with neurologic symptoms and supports the feasibility and efficacy of venetoclax-based intensive chemotherapy for EMR, even after prior HSCT, in pediatric AML patients.<\/jats:p>","DOI":"10.1007\/s00277-025-06647-w","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:22:13Z","timestamp":1761553333000},"page":"6427-6433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bilateral facial palsy as presenting symptom of post-transplant relapsed acute myeloid leukemia treated with venetoclax: a case report and literature review"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7058-091X","authenticated-orcid":false,"given":"Cecilia","family":"Diamanti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5273-4020","authenticated-orcid":false,"given":"Vincenzo","family":"Apolito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Spadea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Ceolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mussano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Tomatis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Quarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Fagioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"10","key":"6647_CR1","doi-asserted-by":"publisher","first-page":"859.e1","DOI":"10.1016\/j.jtct.2021.06.023","volume":"27","author":"V Hazar","year":"2021","unstructured":"Hazar V et al (2021) Different kinetics and risk factors for isolated extramedullary relapse after allogeneic hematopoietic stem cell transplantation in children with acute leukemia. Transplant Cell Ther 27(10):859.e1-859.e10. https:\/\/doi.org\/10.1016\/j.jtct.2021.06.023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"6647_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.bbmt.2017.03.023","volume":"23","author":"N Shem-Tov","year":"2017","unstructured":"Shem-Tov N et al (2017) Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse. Biol Blood Marrow Transplant 23(7):1087\u20131094. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.023","journal-title":"Biol Blood Marrow Transplant"},{"key":"6647_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.03.030","author":"L Ge","year":"2014","unstructured":"Ge L et al (2014) Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia. Biol Blood Marrow Transplant. https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.030","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"6647_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3324\/haematol.2012.073189","volume":"98","author":"AC Harris","year":"2013","unstructured":"Harris AC et al (2013) Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica 98(2):179\u2013184. https:\/\/doi.org\/10.3324\/haematol.2012.073189","journal-title":"Haematologica"},{"key":"6647_CR5","doi-asserted-by":"publisher","unstructured":"Piccini M, Mannelli F, Coltro G (2023) The role of venetoclax in relapsed\/refractory acute myeloid leukemia: past, present, and future directions. Bioengineering 10(5):591. https:\/\/doi.org\/10.3390\/bioengineering10050591","DOI":"10.3390\/bioengineering10050591"},{"issue":"1","key":"6647_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00277-023-05401-4","volume":"103","author":"Q Lin","year":"2024","unstructured":"Lin Q, Ye P, Wang T, Lu Y (2024) Successful use of venetoclax combined with azacitidine in isolated extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report. Ann Hematol 103(1):335\u2013337. https:\/\/doi.org\/10.1007\/s00277-023-05401-4","journal-title":"Ann Hematol"},{"issue":"13","key":"6647_CR7","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/bloodadvances.2023012041","volume":"8","author":"R Masetti","year":"2024","unstructured":"Masetti R, Baccelli F, Leardini D, Locatelli F (2024) Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies? Blood Adv 8(13):3583\u20133595. https:\/\/doi.org\/10.1182\/bloodadvances.2023012041","journal-title":"Blood Adv"},{"issue":"16","key":"6647_CR8","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1182\/bloodadvances.2023010113","volume":"7","author":"R Masetti","year":"2023","unstructured":"Masetti R et al (2023) Venetoclax-based therapies in pediatric advanced MDS and relapsed\/refractory AML: a multicenter retrospective analysis. Blood Adv 7(16):4366\u20134370. https:\/\/doi.org\/10.1182\/bloodadvances.2023010113","journal-title":"Blood Adv"},{"issue":"4","key":"6647_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4103\/ijmpo.ijmpo_142_17","volume":"39","author":"B Shilpi","year":"2018","unstructured":"Shilpi B, Prem S, Madhu R, Rakeev K (2018) Rare initial presentation of acute myeloid leukemia as facial palsy. Indian J Med Paediatr Oncol 39(4):554\u2013555. https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_142_17","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"S2","key":"6647_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s12070-015-0930-8","volume":"71","author":"BS Goh","year":"2019","unstructured":"Goh BS, Tang CL, Tan GC (2019) Myeloid sarcoma of temporal bone: a rare manifestation of relapse acute myeloid leukemia. Indian J Otolaryngol Head Neck Surg 71(S2):1023\u20131026. https:\/\/doi.org\/10.1007\/s12070-015-0930-8","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"6647_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013673","author":"L Wang","year":"2018","unstructured":"Wang L, Wang Z, Wan C, Cai X, Zhang G, Lai C (2018) Facial paralysis as a presenting symptom of infant leukemia: a case report and literature review. Medicine. https:\/\/doi.org\/10.1097\/MD.0000000000013673","journal-title":"Medicine"},{"issue":"4","key":"6647_CR12","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1111\/ped.12384","volume":"56","author":"K Kubota","year":"2014","unstructured":"Kubota K (2014) Facial palsy as an unusual presenting symptom associated with acute myeloid leukemia. Pediatr Int 56(4):e37\u2013e40. https:\/\/doi.org\/10.1111\/ped.12384","journal-title":"Pediatr Int"},{"issue":"2","key":"6647_CR13","first-page":"187","volume":"28","author":"H Poparn","year":"2018","unstructured":"Poparn H, Techavichit P, Chiangthong K, Sosothikul D (2018) Facial palsy as a presentation of relapsed pediatric AML. J Hematol Transfus Med 28(2):187\u2013191","journal-title":"J Hematol Transfus Med"},{"issue":"8","key":"6647_CR14","first-page":"223","volume":"5","author":"S Sharma","year":"2016","unstructured":"Sharma S, Singh S, Mittal A (2016) Facial nerve palsy in childhood acute myeloid leukemia - a rare case report. Int J Sci Res 5(8):223\u2013224","journal-title":"Int J Sci Res"},{"issue":"1","key":"6647_CR15","first-page":"18","volume":"25","author":"C-W Young","year":"2016","unstructured":"Young C-W, Ho C-S, Chiu N-C, Liu H-C, Liang D-C (2016) Acute myeloid leukemia with initial presentation of facial palsy and exophthalmos. Acta Neurol Taiwan 25(1):18\u201320","journal-title":"Acta Neurol Taiwan"},{"key":"6647_CR16","doi-asserted-by":"publisher","unstructured":"Y\u00fccel L, Ba\u015fak H, Beton S (2021) Acute mastoiditis with facial paralysis as initial symptom of acute myeloid leukemia relapse: a rare case report. Egypt J Otolaryngol 37(1):32. https:\/\/doi.org\/10.1186\/s43163-021-00098-6","DOI":"10.1186\/s43163-021-00098-6"},{"issue":"1","key":"6647_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/2229-516x.149256","volume":"5","author":"R Kapoor","year":"2015","unstructured":"Kapoor R, Khunger J, Sharma A, Sachdeva S (2015) The paradox of recurrent with rare: a rare case of bilateral proptosis and facial palsy in acute myeloid leukemia with recurrent cytogenetic translocation t(8:21). Int J Appl Basic Med Res 5(1):76. https:\/\/doi.org\/10.4103\/2229-516x.149256","journal-title":"Int J Appl Basic Med Res"},{"issue":"1","key":"6647_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.22470\/pemj.2017.00010","volume":"4","author":"SH Yoon","year":"2017","unstructured":"Yoon SH, Kim SH, Lee M-J, Lee H-J, Lyu CJ, Kim MK (2017) A 4-year-old girl presenting with facial palsy, found to have increased delta neutrophil index, and diagnosed with acute myeloid leukemia with extramedullary infiltration. Pediatr Emerg Med J 4(1):25\u201328. https:\/\/doi.org\/10.22470\/pemj.2017.00010","journal-title":"Pediatr Emerg Med J"},{"key":"6647_CR19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626","author":"M Heuser","year":"2021","unstructured":"Heuser M (2021) 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"issue":"7","key":"6647_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/nejmoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/nejmoa2012971","journal-title":"N Engl J Med"},{"key":"6647_CR21","doi-asserted-by":"publisher","unstructured":"Liu Y, Li Y, Zhang R, Yu Z, Jing Y (2023) Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed\/refractory AML: a single-center clinical trial. Front Immunol 14:1269163. https:\/\/doi.org\/10.3389\/fimmu.2023.1269163","DOI":"10.3389\/fimmu.2023.1269163"},{"issue":"3","key":"6647_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","volume":"116","author":"F Kreidieh","year":"2022","unstructured":"Kreidieh F (2022) Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Int J Hematol 116(3):330\u2013340. https:\/\/doi.org\/10.1007\/s12185-022-03416-7","journal-title":"Int J Hematol"},{"key":"6647_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1779255","author":"W Pan","year":"2020","unstructured":"Pan W, Zhao X, Shi W, Jiang Z, Xiao H (2020) Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation. Leuk Lymphoma. https:\/\/doi.org\/10.1080\/10428194.2020.1779255","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6647_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3324\/haematol.2024.285985","volume":"110","author":"S Kayser","year":"2024","unstructured":"Kayser S et al (2024) Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax\/hypomethylating agents. Haematologica 110(2):378\u2013384. https:\/\/doi.org\/10.3324\/haematol.2024.285985","journal-title":"Haematologica"},{"issue":"8","key":"6647_CR25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1080\/10428194.2020.1742908","volume":"61","author":"S Otoukesh","year":"2020","unstructured":"Otoukesh S et al (2020) The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. Leuk Lymphoma 61(8):2020\u20132023. https:\/\/doi.org\/10.1080\/10428194.2020.1742908","journal-title":"Leuk Lymphoma"},{"key":"6647_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205075","volume":"13","author":"I Urbino","year":"2021","unstructured":"Urbino I et al (2021) Evolving therapeutic approaches for older patients with acute myeloid leukemia in 2021. Cancers (Basel) 13:5075","journal-title":"Cancers (Basel)"},{"issue":"5","key":"6647_CR27","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","volume":"9","author":"CA Lachowiez","year":"2022","unstructured":"Lachowiez CA et al (2022) Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350\u2013e360. https:\/\/doi.org\/10.1016\/S2352-3026(22)00076-X","journal-title":"Lancet Haematol"},{"key":"6647_CR28","doi-asserted-by":"publisher","unstructured":"Martinelli G et al (2023) Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: a GIMEMA Italian cooperative analysis. J Clin Oncol 41:7013\u20137013. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.7013","DOI":"10.1200\/JCO.2023.41.16_suppl.7013"},{"key":"6647_CR29","doi-asserted-by":"publisher","unstructured":"Wei AH et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137\u20132145. https:\/\/doi.org\/10.1182\/blood.202000485","DOI":"10.1182\/blood.202000485"},{"issue":"4","key":"6647_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","volume":"21","author":"SE Karol","year":"2020","unstructured":"Karol SE et al (2020) Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol 21(4):551\u2013560. https:\/\/doi.org\/10.1016\/S1470-2045(20)30060-7","journal-title":"Lancet Oncol"},{"key":"6647_CR31","doi-asserted-by":"publisher","unstructured":"Pfeiffer T et al (2021) Venetoclax-based combination therapy as a bridge to allogeneic hematopoietic stem cell transplant in children with relapsed\/refractory AML. Bone Marrow Transplant 58;3:328\u2013331. https:\/\/doi.org\/10.1038\/s41409-022-01877-2","DOI":"10.1038\/s41409-022-01877-2"},{"issue":"1","key":"6647_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bjh.19849","volume":"206","author":"S Cousson","year":"2025","unstructured":"Cousson S et al (2025) Monocentric experience of venetoclax-based regimen in paediatric refractory and relapsed AML\/MDS. Br J Haematol 206(1):209\u2013214. https:\/\/doi.org\/10.1111\/bjh.19849","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06647-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06647-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06647-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:58:32Z","timestamp":1768467512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06647-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6647"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06647-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"Written informed consent for publication of this case report and any accompanying images was obtained from the patient\u2019s legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}